Partner Hospitals

Founded in 1964, it is a benchmark for cancer diagnosis and treatment in South China. Annual outpatient and emergency visits reach 2.558 million, and annual inpatient admissions are 222,000. Its medical volume ranks among the top of national oncology-specialized hospitals. It boasts leading medical technologies and an Asia-class radiotherapy center with top-tier hardware and software. Minimally invasive robotic surgeries are performed in multiple specialties. The hospital maintains cooperation with The University of Texas MD Anderson Cancer Center, which ranks No.1 among oncology centers in the United States.

Founded in 1904. The hospital registers more than 5.3 million annual outpatient and emergency visits, over 180,000 annual inpatient admissions, and more than 120,000 annual inpatient operations. The leading specialties including Orthopedics and Endocrinology and Metabolism enjoy nationally top-tier medical capabilities. The cure rates for complex trauma, hand and foot microsurgery, and refractory endocrine diseases rank among the highest in China.

Founded in 1997, it is one of China’s leading private hospital groups. It has established 11 hospitals and 14 clinics in Hong Kong, Beijing, Shanghai, Guangzhou, Shenzhen, Tianjin, Qingdao and other cities. The annual number of patients served exceeds one million, including nearly 100,000 foreign patients. It has built a sizable international medical service network and formed a tiered medical service system of “general hospitals + specialized medical centers + clinics”. It covers a complete medical service chain including family medicine, emergency medicine, women’s health, pediatrics, cardiovascular and cerebrovascular diseases, oncology, urology, gastroenterology, orthopedics, critical care medicine and neuroscience center.

Founded in 1957, it is China’s first Grade A tertiary specialized hospital focusing on the diagnosis and treatment of cardiothoracic diseases after the founding of the People’s Republic of China. Centered on two major discipline clusters: thoracic tumors and cardiovascular diseases, it masters the most extensive spectrum and full range of diagnostic and therapeutic technologies for cardiothoracic diseases in China. Annual outpatient and emergency visits exceed 860,000, with more than 28,000 surgeries performed each year. The proportion of Grade-III and Grade-IV surgeries is over 90%. Its surgical volume for tracheal and mediastinal tumors ranks No.1 nationwide, lung tumor surgery volume ranks No.2 nationwide, and esophageal surgery volume is among the top in China and ranks No.1 in the city.

Founded in 1931. It is equipped with 22 high-end medical devices including Da Vinci surgical robots, MR Linac, TOMO, LA, PET-CT, PET-MR and 5.0T MRI. Annual outpatient visits: 2.5 million; annual inpatient admissions: 170,000; annual surgeries: 80,000; annual radiotherapy sessions: 420,000. The overall 5-year survival rate of patients with malignant tumors reaches 72%.

Founded in 1920. It is the supporting institution for the National Center for Stomatology and the National Clinical Research Center for Oral Diseases. Its Department of Plastic and Reconstructive Surgery remains the world’s largest plastic surgery medical center and China’s leading center for plastic surgery in medical treatment, teaching and research. Annual outpatient and emergency visits exceed 4.8 million, inpatient admissions over 150,000, inpatient surgeries more than 90,000, and outpatient surgical procedures over 170,000.

Founded in 1907. The hospital is equipped with top-tier devices including PET-MR, sixth-generation cranial Gamma Knife, 4th-generation Da Vinci surgical robotic system, intraoperative radiotherapy system and small-animal PET-CT. It also boasts a large array of sophisticated instruments such as PET-CT, Tomotherapy system (TOMO), proton radiotherapy system and 3.0T MRI. The hospital has served more than 80,000 foreign patients in total.